Efficacy of Oseltamivir in the Treatment of Patients Infected With Covid-19

Efficacy of Oseltamivir in the Treatment of Patients Infected With Covid-19 Publisher

Zendehdel A^{1, 2} ; Bidkhori M³ ; Ansari M⁴ ; Jamalimoghaddamsiyahkali S⁵ ; Asoodeh A²

Show Affiliations

1. Geriatrics Department, Associate Professor of Internal Medicine, Ziaeian Hospital, Tehran University of Medical Sciences, Tehran, Iran
2. Family Medicine Department, Ziaeian Hospital, Tehran University of Medical Sciences, Tehran, Iran
3. Department of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
4. Radiology Department, Amir al-Momenin Hospital, Islamic Azad University of Medical Sciences, Tehran, Iran
5. Department of Infectious Disease, School of Medicine, Ziaeian Hospital, Tehran University of Medical Sciences, Tehran, Iran

Source: Annals of Medicine and Surgery Published:2022

Abstract

Objective: The recent unprecedented pandemic caused by Sars-Cov-2 (the new coronavirus 2019), is threatening public health around the world. Although several studies have been performed, there is no identified treatment for Covid-19 patients. Here we assessed the efficacy of oseltamivir in combination therapy, by comparing two different therapeutic regimens in hospitalized patients, in improving outcomes and find better treatment for Covid-19 patients. Methods: This is a single-center retrospective cohort study of 285 confirmed Covid-19 in patients at (XXX). Depending on the date of admission, the patients were divided into two groups; group 1 (oseltamivir group) from February 20, 2020 to March 15, 2020 received Oseltamivir with routine regimen and group 2 (control group) from March 20, 2020 to April 20, 2020 received routine regimen alone that included Azithromycin 500 mg/day and Hydroxychloroquine 200 mg/12 h. Endpoints including duration of hospitalization, requirement to admission to intensive care unit (ICU) and mechanical ventilation, outcome and mortality rate. Results: A total of 285 patients were enrolled in the two months, 120 patients for group 1 and 165 for group 2. The median time from admission to discharge was significantly shorter in the oseltamivir group compared to the control group (4.9 vs 6.6 days, p < 0.001). Additionally, the mortality rate was found to be lower in the oseltamivir group than in the control group (1.7% vs 6,7%, p = 0.06) which was statistically significant by multivariate analysis (p = 0.03). The incidence of admission to the ICU (6.7% vs 11.5%, p = 0.1) and mechanical ventilation (2.5% vs 4.8%, p = 0.3) were also decreased in the oseltamivir group, but was not statistically significant. Conclusions: This study showed that administration of oseltamivir was associated with shorter length of hospital stay and earlier recovery and discharge of hospital, and a lower mortality rate. © 2022 The Authors

Related Docs

View other Related Docs

1. Coli-Net: Deep Learning-Assisted Fully Automated Covid-19 Lung and Infection Pneumonia Lesion Detection and Segmentation From Chest Computed Tomography Images, International Journal of Imaging Systems and Technology (2022)

2. A Review of Covid-19: The Main Ways of Transmission and Some Prevention Solutions, Clinical Symptoms, More Vulnerable Human Groups, Risk Factors, Diagnosis, and Treatment, Journal of Environmental Treatment Techniques (2020)

3. The Use of Remdesivir Among Pregnant Women and Associated Clinical Outcomes in Mother and the Child, Annals of Medicine and Surgery (2022)

4. Green Chemistry and Coronavirus, Sustainable Chemistry and Pharmacy (2021)

5. Precision Medicine in Infectious Disease, Precision Medicine in Clinical Practice (2022)

6. Mesenchymal Stem Cell-Derived Exosomes for Covid-19 Therapy, Preclinical and Clinical Evidence, International Journal of Stem Cells (2021)

7. The Investigation of the Distribution of Abo/Rh Blood Group in Hospitalized Covid-19 Patients and Its Association With Disease Severity, Clinical Outcomes, Lab Tests, and Radiologic Findings, Health Science Reports (2025)

8. Sars-Cov-2: From the Pathogenesis to Potential Anti-Viral Treatments, Biomedicine and Pharmacotherapy (2021)

Experts (# of related papers)

View all Related Experts

Amir Reza Radmard (2)

Seyed Ahmad Seyed Alinaghi (2)

Style	Citing Format
MLA	Zendehdel A, et al.. "Efficacy of Oseltamivir in the Treatment of Patients Infected With Covid-19." Annals of Medicine and Surgery, vol. 77, no. , 2022, pp. -.
APA	Zendehdel A, Bidkhori M, Ansari M, Jamalimoghaddamsiyahkali S, Asoodeh A (2022). Efficacy of Oseltamivir in the Treatment of Patients Infected With Covid-19. Annals of Medicine and Surgery, 77(), -.
Chicago	Zendehdel A, Bidkhori M, Ansari M, Jamalimoghaddamsiyahkali S, Asoodeh A. "Efficacy of Oseltamivir in the Treatment of Patients Infected With Covid-19." Annals of Medicine and Surgery 77, no. (2022): -.
Harvard	Zendehdel A et al. (2022) 'Efficacy of Oseltamivir in the Treatment of Patients Infected With Covid-19', Annals of Medicine and Surgery, 77(), pp. -.
Vancouver	Zendehdel A, Bidkhori M, Ansari M, Jamalimoghaddamsiyahkali S, Asoodeh A. Efficacy of Oseltamivir in the Treatment of Patients Infected With Covid-19. Annals of Medicine and Surgery. 2022;77():-.
BibTex	@article{ author = {Zendehdel A and Bidkhori M and Ansari M and Jamalimoghaddamsiyahkali S and Asoodeh A}, title = {Efficacy of Oseltamivir in the Treatment of Patients Infected With Covid-19}, journal = {Annals of Medicine and Surgery}, volume = {77}, number = {}, pages = {-}, year = {2022} }
RIS	TY - JOUR AU - Zendehdel A AU - Bidkhori M AU - Ansari M AU - Jamalimoghaddamsiyahkali S AU - Asoodeh A TI - Efficacy of Oseltamivir in the Treatment of Patients Infected With Covid-19 JO - Annals of Medicine and Surgery VL - 77 IS - SP - EP - PY - 2022 ER -

Science Communicator Platform

Authors

Authors Affiliations

Abstract